Equities Analysts Issue Forecasts for Black Diamond Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:BDTX)


Black Diamond Therapeutics, Inc. (NASDAQ:BDTXFree Report) – HC Wainwright boosted their Q1 2024 earnings per share estimates for shares of Black Diamond Therapeutics in a note issued to investors on Monday, March 18th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.44) per share for the quarter, up from their prior estimate of ($0.51). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q2 2024 earnings at ($0.45) EPS, Q3 2024 earnings at ($0.47) EPS, Q4 2024 earnings at ($0.48) EPS and FY2024 earnings at ($1.84) EPS.

Separately, Wedbush reissued an “outperform” rating and set a $10.00 price objective on shares of Black Diamond Therapeutics in a report on Wednesday, March 13th.

Read Our Latest Research Report on Black Diamond Therapeutics

Black Diamond Therapeutics Stock Performance

Shares of Black Diamond Therapeutics stock opened at $4.63 on Wednesday. Black Diamond Therapeutics has a 52-week low of $1.43 and a 52-week high of $6.85. The stock’s 50-day simple moving average is $4.03 and its 200 day simple moving average is $3.11. The stock has a market capitalization of $239.46 million, a P/E ratio of -2.46 and a beta of 2.65.

Institutional Trading of Black Diamond Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of BDTX. Jump Financial LLC purchased a new stake in Black Diamond Therapeutics in the third quarter worth approximately $32,000. Cubist Systematic Strategies LLC boosted its stake in Black Diamond Therapeutics by 25.8% in the second quarter. Cubist Systematic Strategies LLC now owns 15,804 shares of the company’s stock worth $39,000 after buying an additional 3,244 shares in the last quarter. Walleye Capital LLC purchased a new stake in Black Diamond Therapeutics in the third quarter worth approximately $44,000. AQR Capital Management LLC boosted its stake in Black Diamond Therapeutics by 34.4% in the second quarter. AQR Capital Management LLC now owns 18,663 shares of the company’s stock worth $46,000 after buying an additional 4,773 shares in the last quarter. Finally, Algert Global LLC purchased a new stake in Black Diamond Therapeutics in the third quarter worth approximately $57,000.

Black Diamond Therapeutics Company Profile

(Get Free Report)

Black Diamond Therapeutics, Inc, a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company’s lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial.

Recommended Stories

Earnings History and Estimates for Black Diamond Therapeutics (NASDAQ:BDTX)



Receive News & Ratings for Black Diamond Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Black Diamond Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.


Source link

Check Also

Equities Analysts Set Expectations for Green Dot Co.’s Q1 2025 Earnings (NYSE:GDOT)

Green Dot Co. (NYSE:GDOT – Free Report) – Stock analysts at Northland Capmk issued their …

Leave a Reply

Your email address will not be published. Required fields are marked *